Case study: risperidone in children and adolescents with schizophrenia.
Schizophrenia in children is an uncommon disorder with devastating effects. Study of the efficacy of treatment with neuroleptics in children with schizophrenia is only now beginning, and there are limited studies on the effectiveness of novel neuroleptics on the positive and negative symptoms of schizophrenia in children. Four patients with schizophrenia, aged 12 to 17 years, were treated with risperidone (4 to 5 mg/day), a 5-HT2/D2 receptor blocking agent, to determine its effectiveness. Three patients had substantial improvement in their negative symptoms without side effects.